Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ) December 14, 2018 16:15 CET Regulatory Read more
Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ) November 14, 2018 08:00 CET Regulatory Read more
First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon November 13, 2018 16:20 CET Regulatory Read more
Calliditas Therapeutics to present and attend investor conferences in November 2018 November 9, 2018 14:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update October 30, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2019 October 4, 2018 10:00 CET Regulatory Read more
Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study October 1, 2018 08:00 CET Non Regulatory Read more
Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN) September 25, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update August 13, 2018 08:00 CET Non Regulatory Read more
The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts August 6, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry August 1, 2018 08:00 CET Non Regulatory Read more
Exercise of over-allotment option and end of the stabilization period July 29, 2018 18:30 CET Regulatory Read more
Trading in Calliditas’ share commences today on Nasdaq Stockholm June 29, 2018 08:00 CET Non Regulatory Read more
Calliditas announces listing on Nasdaq Stockholm and related prospectus June 15, 2018 05:00 CET Regulatory Read more